Screening Tests for Adults (50 and Up)

Breast cancer is the second most commonly diagnosed cancer in American women and a leading cause of cancer death. Almost 70% of breast cancers are found in women 55 or older. Regular screening can help to detect tumors at an early stage when they are most treatable. Mammography is an imaging test that can detect breast cancer before symptoms develop.

The medical community recognizes the value of breast cancer screening and mammography, but there are some differences in the advice on how often it should be done or when it should be started. Most organizations agree that women should work with their healthcare practitioner to assess their personal risk of developing breast cancer and to determine what is best for them. Considerations can be given to the benefits of screening as well as the harms. While screening can detect cancer early when it is most treatable, it may also lead to false-positive results and unnecessary follow-up procedures, such as biopsies.

Recommendations for women with average risk:

Women with average risk have no personal or family history of breast cancer and no other risk factors for breast cancer.

Clinical Breast Exams

• The American College of Obstetricians and Gynecologists (ACOG) and the National Comprehensive Cancer Network (NCCN) say that, starting at age 40, women should be offered a clinical breast exam by a health professional yearly as part of their regular health exam.
• The U.S. Preventive Services Task Force (USPSTF) and the American Cancer Society (ACS) state that there is insufficient evidence or that they do not recommend clinical breast examinations for women at any age.

Breast self-awareness is important, according to ACOG. Women of all ages should discuss breast self-awareness with their healthcare provider and immediately report any change in their breasts' normal appearance and feel. These changes could include pain, a mass, nipple discharge other than breast milk, or redness.

Mammograms

Ages 50 to 74

• ACOG recommends screening with a mammogram every 1 to 2 years.
• The American Medical Association (AMA) and NCCN recommend screening with a mammogram every year.
• ACS recommends women aged 45-54 have an annual mammogram; women aged 55 and older have the option to switch to mammograms every 2 years or continue with annual screening.
• USPSTF and the American College of Physicians (ACP) recommend that women ages 50 to 74 should have a routine screening mammogram every 2 years.

Age 75 and Older

• ACOG says that the decision to screen beyond age 75 should be made by a woman and her healthcare practitioner (shared decision) and should take into account her health and longevity.
• ACS and NCCN say that mammography screening should continue as long as a woman is in good health and she is expected to live for 10 years or longer.
• USPSTF and ACP have stated that current evidence is insufficient to determine whether there are additional benefits and harms from screening mammography in women 75 years or older and makes no specific recommendation for this age group.

Increased Risk

Family history and genetics can contribute to a high lifetime risk. Other risk factors for breast cancer include a personal history of breast cancer, obesity, beginning your period at a younger age, having your first child after age 35, never giving birth, postmenopausal hormone therapy, beginning menopause at an older age, and alcohol consumption.

Some of the important factors contributing to a high lifetime risk include:

• Carrying a mutated BRCA1 or BRCA2 gene or having a close relative with the gene
• Having had chest radiation at a young age (between 10 and 30 years old)
• Certain family histories, such as multiple close relatives with breast or ovarian cancer

ACS recommends that women at high lifetime risk be screened with magnetic resonance imaging (MRI) in addition to mammography annually beginning at age 30 and continuing as long as they are in good health.

If you suspect you are at an increased risk for breast cancer, you should consult your healthcare provider and consider developing an individualized screening program.

---

Links
American Cancer Society: Breast Cancer Risk and Prevention
National Cancer Institute: Breast Cancer Screening 

---

Sources Used in Current Review (last reviewed 2/4/19)

(September 10, 2018) National Institutes of Health, National Cancer Institute. Surveillance, Epidemiology, and End Results Program. Cancer stat facts: Female breast cancer. Available online at https://seer.cancer.gov/statfacts/html/breast.html. Accessed on January 2019.

(September 11, 2018) Centers for Disease Control and Prevention. Breast cancer: What is breast cancer screening? Available online at https://www.cdc.gov/cancer/breast/basic_info/screening.htm. Accessed January 2019.

(July, 2017) American College of Obstetricians and Gynecologists (ACOG). ACOG Practice Bulletin. Clinical management guidelines for obstetrician-gynecologists. Available online at https://www.acog.org/Clinical-Guidance-and-Publications/Practice-Bulletins/Committee-on-Practice-Bulletins-Gynecology/Breast-Cancer-Risk-Assessment-and-Screening-in-Average-Risk-Women. Accessed January 2019.

(January, 2016) U.S. Preventative Services Task Force. Breast cancer: Screening. Available online at https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/breast-cancer-screening1. Accessed on January 2019.

Oeffinger K.C., et al. American Cancer Society. Breast cancer screening for women at average risk: 2015 guideline update from he American Cancer Society. 2015;314:1599-614. Journal of the American Medical Association. Available online at http://dx.doi.org/10.1001/jama.2015.12783. Accessed on January 2019.

(October 9, 2017). American Cancer Society. Breast cancer early detection and diagnosis. Available online at https://www.cancer.org/cancer/breast-cancer/screening-tests-and-early-detection/american-cancer-society-recommendations-for-the-early-detection-of-breast-cancer.html. Accessed January 2019.

(January, 2016) Facing Our Risk of Cancer Empowered. Comparison of breast cancer screening guidelines. Available online at http://www.facingourrisk.org/our-role-and-impact/advocacy/documents/breast-screening-comparison-chart.pdf. Accessed January 2019.

(May 18, 2018) National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Breast cancer screening and diagnosis. Available online at https://www.nccn.org/professionals/physician_gls/pdf/breast-screening.pdf. Accessed January 2019.

Most deaths from cancer of the cervix (the lower part of the uterus, or womb) could be avoided if women had regular gynecological checkups with Pap tests and/or HPV DNA tests.

Nearly all cervical cancers are caused by human papilloma virus (HPV), but not all HPV strains cause cervical cancer. About a dozen HPV strains, such as HPV 16, 18, 33, 35, and 39, are considered "high risk" because persistent infections — those that do not resolve without treatment — are linked to an increased risk for cervical and vaginal cancer. Two HPV types, 16 and 18, cause 70% of all cervical cancers.

Cervical cancer is a slow-growing cancer that can take several years to develop and most often is seen in women 40 years of age or older. Routine screening can help identify cervical cancer early on, at a time when it is highly curable. Screening even finds precancerous lesions so they can be removed before cancer ever starts.

Recommendations: Ages 50 to 65 | Over age 65

The American College of Obstetricians and Gynecologists (ACOG), the U.S. Preventive Services Task Force (USPSTF), and the American Cancer Society (ACS) recommend that women ages 50 to 65 have a Pap test and an HPV test every 5 years, although a Pap test alone every 3 years is also acceptable.

Women who haven't been screened for cervical cancer for several years or who have never been tested are especially urged to have a Pap test.

Significant changes to these recommendations may be on the horizon, however. The Food and Drug Administration (FDA) approved an HPV DNA test as a primary screening tool for cervical cancer, meaning it may be used without a Pap test. Individual health organizations have yet to update their screening recommendations, but an expert panel issued interim (temporary) guidelines in 2015. These guidelines say that:

• The HPV test may be offered to women aged 25 and older without a Pap test.
• If initial results are negative, women should be screened again no sooner than 3 years.

Women interested in this new option should talk to their healthcare provider. The interim guidelines acknowledge that more studies are needed to further evaluate the HPV test and its role in cancer screening. For example, there are still questions about whether age 25 is the best age to start offering it as a primary screening option and how often women should be screened.

Recommendations: Over age 65 | Ages 50 to 65 

ACOG, USPSTF and ACS recommend against screening for cervical cancer for women over the age of 65 who have had negative results on adequate prior screening. Guidelines define adequate prior screening as 3 consecutive negative Pap tests or 2 consecutive negative HPV tests in the prior 10 years, with the most recent within 5 years.

Risk Factors

How often you should be tested depends on your risk factors. Risk factors include persistent infection with a high-risk strain of HPV, exposure to diethylstilbestrol (DES) in utero, previous diagnosis of cervical cancer, HIV infection, or a compromised immune system. (See the section on Risk Factors in the Cervical Cancer article.) If you have these risk factors, you may be tested more frequently. Ask your healthcare provider for a recommendation on frequency and if this test is still appropriate for you. If you have had a hysterectomy, discuss whether continued screening is of value. In some cases, it is.

Even if you do not need a Pap test each year, for most women an annual well-woman exam is still recommended, reminds ACOG.

---

Link
National Cancer Institute: What You Need To Know About Cervical Cancer

---

Sources Used in Current Review

(Updated 2012 August 13). HPV- Associated Cancer Diagnosis by Age. Centers for Disease Control and Prevention. Available online at http://www.cdc.gov/cancer/hpv/statistics/age.htm. Accessed 6/16/15.

(2012 March). Screening for Cervical Cancer. U.S. Preventive Services Task Force. Available online at http://www.uspreventiveservicestaskforce.org/uspstf/uspscerv.htm. Accessed 6/16/15.

Moyer, VA on behalf of the U.S. Preventive Services Task Force. (2012 June 19). Screening for Cervical Cancer: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine, 156(5). Available online at http://www.annals.org/content/early/2012/03/14/0003-4819-156-12-201206190-00424.full. Accessed 6/16/15.

(Reviewed 2014 March 17). Cervical Cancer Prevention and Early Detection. American Cancer Society. Available online at http://www.cancer.org/acs/groups/cid/documents/webcontent/003167-pdf.pdf. Accessed 6/16/15.

(Reviewed 2014 September 9). Pap and HPV Testing. National Cancer Institute. Available online at http://www.cancer.gov/types/cervical/pap-hpv-testing-fact-sheet. Accessed 6/16/15.

Saslow, D. et al. (2012 March 14). American Cancer Society, American Society for Colposcopy and Cervical Pathology, and American Society for Clinical Pathology screening guidelines for the prevention and early detection of cervical cancer. Available online at http://onlinelibrary.wiley.com/doi/10.3322/caac.21139/full. Accessed 6/16/15.

Barclay, L. (2015 January 9). New Guidance Recommends HPV DNA Test for Primary Screening. Medscape Medical News. Available online at http://www.medscape.com/viewarticle/837832. Accessed 6/16/15.

Prostate cancer is the second most frequently diagnosed cancer in men, after skin cancer. It is also the second leading cause of cancer death, after lung cancer. As many as 1 in 7 American men will develop it during their lifetime, with most cases diagnosed in men 65 years of age or older. Some prostate cancers progress quickly and cause death within months or a few years, but most grow slowly and never pose a major health threat.

Screening for prostate cancer is important for men to discuss with their healthcare providers. Many complicated issues are involved:

• Current technology cannot tell a slow-growing cancer from a fast one, and the cancer may never significantly affect a man's health or life expectancy.
• Screening tests for prostate-specific antigen (PSA) do not detect all cases, and some elevated PSA results do not prove to be cancer.
• Diagnosis through biopsy (with a small risk of infection and bleeding) and side effects of treatment (which could cause erectile dysfunction and incontinence) can potentially be harmful. Most prostate cancers are slow-growing and may not cause any trouble.
• Results from long-term trials on whether PSA testing improves prostate-cancer survival rates has been inconclusive.
   

Informed decisions
In spite of the questions surrounding prostate cancer screening, most health organizations agree that men should receive balanced information about prostate cancer screening and recommend that men discuss it with their healthcare provider.

You need to know the risks, uncertainties, benefits, and limits of prostate cancer testing and treatment and should work with your healthcare provider to understand your options and decide what is best for you. Before choosing prostate screening, you should weigh the pros and cons based on your age, life expectancy, family history, race, overall health, previous test results, and individual risk tolerance.

Risk

One important factor to consider when deciding whether to undergo screening is your personal risk of developing prostate cancer:

• Average risk: Healthy men with no known risk factors
• Increased risk: African American men or men who have a father or brother who was diagnosed before they were age 65
• High risk: Men with more than one relative who was affected at an early age
   

Tests

If you choose to be tested, the following tests may be recommended:

• Prostate specific antigen (PSA)—blood test that measures the level of PSA in the blood
• Digital rectal exam (DRE)—part of a physical exam that the health practitioner performs to manually examine the prostate gland
   

Recommendations: Ages 50 to 70
Most organizations recommend prostate cancer screening only after men discuss the advantages and disadvantages of PSA-based screening for prostate cancer with their healthcare practitioners and make informed decisions. You should consider your own tolerances for risk and uncertainty and how you will use the test results.

• The U.S. Preventive Services Task Force (USPSTF) advises men ages 55 to 69 to make an individual decision about PSA screening with their healthcare practitioner. The decision is based on the harm that can come from false-positive PSA test results which then may lead to surgical or radiation treatment that ultimately will provide little benefit.
• The American Cancer Society (ACS) recommends screening for men 50 years of age and older, with average risk and a life expectancy of at least 10 years who choose to be screened. ACS recommends testing at a younger age for higher-risk groups. If you are in one of these groups, you may want to consider ongoing testing or starting it now. ACS recommends re-screening every two years if your PSA level is less than 2.5 ng/mL and annual screening if it is 2.5 ng/mL or higher.
• The American Urological Association (AUA) recommends men at average risk wait to have a baseline PSA and DRE until age 55, and regular screening from age 55 to 69 for men who wish to be screened. For men younger than age 55 who are at increased or high risk, AUA advises that decisions regarding prostate cancer screening be individualized based on patient preferences and an informed discussion about benefits and harms. AUA recommends regular PSA and DRE testing regardless of whether your PSA was high or low or if the DRE was abnormal.
• The American College of Physicians (ACP) advises men 50 to 69 years old who are in good health to discuss the benefits and harms of screening with their healthcare practitioners and to get screened if they decide to do so. A PSA blood test may be done every 2 to 4 years.
• The National Comprehensive Cancer Network (NCCN) recommends a baseline test at age 45 for men who want screening, which then will determine when and how often to have future tests—and if you haven't yet had a baseline test, consider getting tested now. NCCN advises using the DRE and the PSA test in combination for the broadest detection of cancer in its early stages. If the PSA test result is greater than 1.0 ng/mL, or the man is at higher risk, NCCN recommends DRE and PSA tests at one- to two-year intervals.
   

Recommendations: Over age 70 

• USPSTF recommends against screening men older than 70. It found that potential harms from prostate screening outweigh the benefits for men at an age where prostate cancer is not likely to cause death.
• ACS and AUA emphasize that overall health, not just age, is an important consideration for older men when deciding to be screened. They recommend that men with a life expectancy less than 10 years not be screened. AUA notes that some men who are otherwise in excellent health and over the age of 70 could benefit from screening and urges those men to talk with their doctors about it.
• ACP advises against screening men over age 69.
• NCCN emphasizes that men over 70 should receive individual consideration for their overall health, previous PSA results, family history, and risk factors before deciding to screen and how frequently they should get screened for prostate cancer. For men over 75, NCCN recommends that testing should be done only in very healthy men to detect rare, but aggressive prostate cancers.

 

---

Link

Articles: Making Informed Decisions for Better Health
 

---

Sources Used in Current Review (Latest review 6/25/2018)

(March 11, 2016) American Cancer Society. About Prostate Cancer. Available online at https://www.cancer.org/content/dam/CRC/PDF/Public/8793.00.pdf. Accessed on June 22, 2018.

(March 11, 2016) American Cancer Society. Prostate Cancer Risk Factors. Available online at https://www.cancer.org/cancer/prostate-cancer/causes-risks-prevention/risk-factors.html. Accessed on June 22, 2018.

(April 14, 2016) American Cancer Society. If Prostate Cancer Screening Test Results Aren’t Normal. Available online at https://www.cancer.org/cancer/prostate-cancer/early-detection/if-test-results-not-normal.html. Accessed on June 22, 2018.

(April 14, 2016). American Cancer Society. Recommendations for Prostate Cancer Early Detection. Available online at https://www.cancer.org/cancer/prostate-cancer/early-detection/acs-recommendations.html. Accessed on June 22, 2018.

(April 5, 2018) National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology: Prostate Cancer Early Detection. Available online at https://www.nccn.org/professionals/physician_gls/pdf/prostate_detection.pdf. Accessed on June 22, 2018.

(May 8, 2018) U.S. Preventive Services Task Force Bulletin. USPSTF Issues Final Recommendation on Screening for Prostate Cancer. Available online at https://www.uspreventiveservicestaskforce.org/Home/GetFile/6/250/prostate-cancer-final-rec-statement-bulletin/PDF. Accessed on June 22, 2018.

(May 2018) U.S. Preventive Services Task Force. Final Recommendation Statement: Prostate Cancer: Screening. Available online at https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/prostate-cancer-screening1. Accessed on June 22, 2018.

(May 5, 2018) American Urological Association. Press release: AUA Responds to USPSTF Final Recommendations on Screening for Prostate Cancer. Available online at http://auanet.mediaroom.com/2018-05-08-AUA-Responds-to-USPSTF-Final-Recommendations-on-Screening-for-Prostate-Cancer. Accessed on June 22, 2018.

(2015) American Urological Association. Clinical Guidelines: Early Detection of Prostate Cancer. Available online at http://www.auanet.org/guidelines/early-detection-of-prostate-cancer-(2013-reviewed-and-validity-confirmed-2015). Accessed on June 22, 2018.

(19 May 2015) American College of Physicians. Screening for Cancer, Summary for Patients. Available online at http://annals.org/aim/fullarticle/2293232/screening-cancer. Accessed June 2018.

Colon cancer (cancer of the colon and/or rectum) is the uncontrolled growth of abnormal cells within the layers of tissue that line the colon. It is the third most common non-skin cancer in adults and the third leading cause of cancer deaths in men and women in the United States. The lifetime risk of developing colon cancer is about 1 in 21 (or 4.7%) for men and 1 in 23 (4.4%) for women, according to the American Cancer Society (ACS).

Over the last several years, the number of deaths from colon cancer has dropped significantly. Improved screening has led to removal of more pre-cancerous polyps, preventing the development of cancer. Likewise, better screening has detected more cancers in the earlier stages, when they are most treatable.

But while the incidence of colon cancer has decreased over the last several years in people age 55 and older due in part to effective screening, there has been a 51% increase in colon cancer among people younger than age 50 since 1994. In 2018, the ACS lowered their recommended starting age for colon cancer screening to age 45 for people with an average risk of colon cancer. If you haven’t already begun screening, you may consider it now.

Furthermore, if you have one or more risk factors for colon cancer you should talk to your healthcare practitioner who can help you assess your individual risk factors and determine if you should get screened more frequently. As the Centers for Disease Control and Prevention (CDC) notes, any of the recommended tests is better than no test.

Screening Recommendations 

Several health organizations have colon cancer screening recommendations. In 2017, screening guidelines for the early detection of pre-cancerous polyps and colon cancer were released by the US Multi-Society Task Force (MSTF) on Colorectal Cancer. The US Preventive Services Task Force released updated similar recommendations in 2016 and the American Cancer Society (ACS) updated their guidelines in 2018. While these groups may differ on which tests to use and how often, they each support screening for colon cancer. Recommendations are based on your age and level of risk.

Increased and High Risk: 
Risk of colon cancer increases with age, being overweight or obese, and with the occurrence of cancers in other parts of the body. Examples of other risk factors include:

• Family history—having one or more family members with colon cancer or multiple polyps, especially if they were younger than age 60 at diagnosis
• Diet—high fat and meat diets are risk factors, especially combined with not eating enough fruits, vegetables, and/or high-fiber foods
• Lifestyle—these risk factors include cigarette smoking, drinking excessive amounts of alcohol, and lack of regular exercise
• Having ulcerative colitis, a form of inflammatory bowel disease
• Having type 2 diabetes
• Racial or ethnic background—African Americans and Ashkenazi Jews have higher risk and rates of colon cancer compared to others.
• Having a personal history of colon cancer and/or high risk precancerous polyps
• Having a rare inherited disease called familial adenomatous polyposis (FAP)—this causes benign polyps to develop early in life and causes cancer in almost all affected persons unless the colon is removed. (See the Genetics Home Reference article on FAP)
• Having a genetic syndrome called Lynch syndrome (hereditary non-polyposis colon cancer or HNPCC) (See the Genetics Home Reference article on Lynch syndrome.)
   

People with increased or high risk of colon cancer may be advised to start screening at a younger age (e.g. age 40). A colonoscopy is usually recommended because it is the most accurate and thorough. Also, the recommended screening interval for high-risk individuals is shorter than for people with average risk (such as every 1-2 years compared to every 10 years).

Additionally, people who have been screened and found to have colon cancer or high risk pre-cancerous polyps also need more frequent re-testing, usually at least every 3 years. (This is called surveillance.) For example, the MSTF guidelines advise enhanced surveillance for people with 3-10 small tubular adenomas as well as those with 1 or more high-risk polyps (i.e., villous features, larger than 10 mm diameter tubular adenoma or serrated sessile polyp, or any polyp that has very atypical features, called high grade dysplasia). On the other hand, those with 1-2 small (less than 10 mm) tubular adenomas in the colon can be re-screened at normal intervals (i.e., every 10 years). Another common polyp, termed a hyperplastic polyp, is not felt to increase risk of colon cancer.

For more information on these types of polyps, read the American Cancer Society’s webpage Understanding Your Pathology Report: Colon Polyps

Average Risk

Ages 50 to 75:
This includes people with no known risk factors other than age. The ACS recommends that all average-risk people begin screening at age 45. Both the MSTF and the USPSTF recommend that people with average risk for colon cancer begin screening at age 50. MSTF recommends that African-Americans begin at age 45.

In 2016, the Canadian Task Force on Preventive Health Care (CTFPHC) issued colon cancer screening recommendations that differ in part from U.S. groups. It recommends that adults aged 50 to 74 years be screened with guaiac-based fecal occult blood test (gFOBT) or FIT every 2 years or flexible sigmoidoscopy every 10 years and recommends against using colonoscopy for primary screening.

Ages 76 to 85: 
The MSTF and USPSTF have similar guidelines recommending that the decision to screen for colon cancer in people aged 76 to 85 should be an individual one based the overall health of the individual and prior screening history. Screening would be most beneficial for those who have never had screening. It is also most appropriate for people healthy enough to undergo treatment if necessary and for those who do not have other underlying conditions that would affect their life expectancy.

The Canadian Task Force on Preventive Health Care recommends against screening people age 75 and older.

Screening Tests
The following table summarizes the screening tests that are options for people with average risk. Tier 1 tests are the tests of choice, according to the MSTF, while tier 2 tests have some disadvantages compared to tier 1 tests. The ACS guidelines do not prioritize a particular screening test and instead says patients and their healthcare practitioners should choose from among several tests based on the patient's preference.

TEST	DESCRIPTION	SCREENING INTERVAL FOR PEOPLE AT AVERAGE RISK	PROS	CONS
Tier 1 tests
Colonoscopy	Examination of the rectum and entire colon with a lighted instrument	Every 10 years	Can examine the entire colon Detects pre-cancerous polyps and cancer Can remove polyps and take biopsies for pathological testing	Extensive full bowel preparation ahead of time Sedation needed to perform Takes at least one day for prep and recovery Risk of bleeding, infection or bowel tears
Fecal Immuno-chemical test (FIT)	Test to detect hidden blood in stool samples	Annually	No dietary or drug restrictions No bowel preparation No direct risk to bowel Samples can be collected at home	Cannot detect precancerous changes May miss some cancers May need to have colonoscopy if positive result
Tier 2 tests
Flexible sigmoidoscopy	Examination of the rectum and lower colon with a rigid or flexible lighted instrument	Every 5-10 years	Minimal preparation ahead of time Detects pre-cancerous polyps and cancer Does not usually need sedation Fairly quick and safe	Only examines about 30% of colon Small risk of bleeding, infection or bowel tear May need to have colonoscopy if abnormal result found
Virtual colonoscopy (CTC, or computed tomographic colonography)	Examination of the rectum and entire colon to the small intestine using x-rays and computers; tube inserted in rectum and bowel is inflated with air	Every 5 years	No sedation required Can view entire colon Detects pre-cancerous polyps and cancer Relatively safe; minimal risk of tear to colon	Full bowel preparation required May need standard colonoscopy if abnormal results Effectiveness as a screening tool is not fully accepted
Fecal Immunochemical test (FIT)-DNA	Detects blood and mutations in specific genes associated with colon cancer in DNA isolated from a stool sample	Every three years, according to the American Cancer Society and MSTF	No bowel preparation or dietary restrictions Sample can be collected at home No risk of bowel tear	Cannot detect precancerous changes Not as effective as annual FIT Adequate stool sample must be obtained Special handling needed May need colonoscopy if abnormal result found
Capsule colonoscopy	Examination of the colon performed by swallowing an indigestible pill with embedded video cameras	Every 5 years per MSTF	Detects pre-cancerous polyps and cancer No sedation required Relatively safe	May need standard colonoscopy if abnormal results Not approved by the FDA for screening people at average risk
No Tier recommendation
Guaiac-based fecal occult blood test (gFOBT) stool test	Test to detect hidden blood in stool sample	Annually	No bowel preparation No direct risk to bowel Sample can be collected at home	Dietary restrictions before testing Cannot detect precancerous changes Detects any blood, not just from cancers but from food or dental procedures May need colonoscopy if positive result

In addition to screening tests, a healthcare practitioner may perform a digital rectal examination (DRE) to feel for a rectal mass with a gloved finger. The DRE is primarily performed to examine the prostate gland, but also allows for the examination of the lower rectum, pelvis, and belly. Most colon cancers, however, are beyond the detection range of a DRE.

If a test other than colonoscopy gives a result suggestive of polyps or cancer, a colonoscopy is often done to examine the full colon and remove polyps or potentially cancerous areas.

Decision Aids

Because any invasive procedure carries some level of risk, you should talk to your healthcare provider about the screening tests recommended for you. Some employers, health plans, and health practitioners offer decision aids.

Also, don't neglect the protection of getting re-tested at the interval recommended by your healthcare provider.

---

Links
Tests: Fecal Occult Blood Test and Fecal Immunochemical Test

Condtions: Colon Cancer

---

Sources Used in Current Review (September 17, 2018)

(2016 June). Colorectal Cancer: Screening. US Preventive Services Task Force. Available online at https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/colorectal-cancer-screening2?ds=1&s=colon. Accessed on September 2018.

Rex DK, Boland CR, Dominitz JA, et al. Colorectal Cancer Screening: Recommendations for Physicians and Patients from the U.S. Multi-Society Task Force on Colorectal Cancer. Am J Gastroenterol. 2017; 112(7):1016–1030. Available online at http://www.nature.com/articles/ajg2017174. Accessed on 9/12/2018.

Canadian Task Force on Preventive Health Care. Recommendations on screening for colorectal cancer in primary care. Canadian Med Assoc J. 2016 Mar 15; 188(5): 340–348. Available online at https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4786388/. Accessed 9/12/2018.

Wolf AMD, Fontham ETH, Church TR, et al. Colorectal cancer screening for average‐risk adults: 2018 guideline update from the American Cancer Society. CA Cancer J Clin. 2018; 68(4):250-281. First published: 30 May 2018. Available online at https://doi.org/10.3322/caac.21457 https://onlinelibrary.wiley.com/doi/full/10.3322/caac.21457. Last accessed 9/12/2018.

HIV is the virus that causes AIDS (acquired immunodeficiency syndrome), a life-threatening disease. Initially, an HIV infection may cause no symptoms or cause non-specific, flu-like symptoms that resolve after a short time period. The only way to determine whether a person has been infected is through HIV testing.

If the infection is not detected and treated, eventually symptoms of AIDS emerge and begin to progressively worsen. Without treatment, HIV destroys the immune system over time and leaves a person's body vulnerable to debilitating infections.

HIV is spread in the following ways:

• By having sex with an infected partner
• By sharing needles or syringes (such as with intravenous injection drug abuse)
• During pregnancy or birth; if a pregnant woman is infected with HIV, the virus can be passed to and infect her developing baby.
• Through contact with infected blood
• In the U.S. today, because of screening blood for transfusion and heat-treating techniques and other treatments of blood derivatives, the risk of getting HIV from transfusions is extremely small. However, before donated blood was screened beginning in 1985 in the U.S. and before treatments were introduced to destroy HIV in some blood products, such as factor 8 and albumin, HIV was transmitted through transfusion of contaminated blood or blood components.

Why Get Screening?
Screening for HIV is now part of routine healthcare in the United States and is an important part of wellness and prevention. This is because diagnosis early in the course of infection leads to timely, effective treatment that decreases the risk of progression to AIDS. A major National Institutes of Health (NIH) clinical trial published in 2015 found that individuals with HIV have a lower risk of developing AIDS and other serious illnesses if they start antiretroviral therapy sooner rather than later.

Early diagnosis also has important benefits for others and society at large. Thousands of people are diagnosed with HIV each year, and about 1 in 8 people in the United States with HIV are unaware that they have it. An individual can prevent further disease spread by learning their status, modifying behavior and not exposing others to infected blood or body fluids. Pregnant women who have HIV can start treatment to prevent spreading the disease to their children.

If an HIV screening test shows a person is not infected, he or she can take steps to avoid infection. For individuals who are HIV-negative but at high risk for HIV, the Centers for Disease Control and Prevention (CDC) and the World Health Organization (WHO) recommend that they consider taking pre-exposure prophylaxis (PrEP), a daily pill to help prevent infection. For people taking PrEP consistently, the risk of HIV infection is significantly lower compared to those who did not take it.

Know Your Risk
Several situations put you at high risk of contracting HIV:

• You've had unprotected sex with more than one partner.
• You have or have had a sexually transmitted disease (STD), which appears to make people more susceptible to and at higher risk for acquiring HIV infection during sex with infected partners.
• You're a man who has had sexual contact with another man.
• You have exchanged sex for money or drugs or had anonymous sex.
• You use or used injection drugs and are likely to have shared unsterilized needles.
• You have an HIV-positive sexual partner.
• You have had sex with anyone who falls into one of the categories listed above or are uncertain about your sexual partner's risk behaviors.
• You've been diagnosed with or treated for hepatitis or tuberculosis (TB).

How often you are tested should depend on your risk, activities, and sexual contacts. For example, during a long-term, truly monogamous sexual relationship, you may want just one test. However, if you or your partner have had sexual contact with more than one person in recent months, your risk of infection is greater. If you or a person with whom you've had sexual contact (even unwanted sexual contact) engaged in some risky behavior, you have even more reason to be tested.

Screening Tests
Different types of tests are available for HIV screening:

• Combination HIV antibody and HIV antigen test—this is the recommended screening test for HIV. It is available only as a blood test. It detects the HIV antigen called p24 plus antibodies to HIV-1 and HIV-2. (HIV-1 is the most common type found in the United States, while HIV-2 has a higher prevalence in parts of Africa.) By detecting both antibody and antigen, the combination test increases the likelihood that an infection is detected soon after exposure. These tests can detect HIV infections in most people by 2-6 weeks after exposure.
• HIV antibody testing—all HIV antibody tests used in the U.S. detect HIV-1, and some tests have been developed that can also detect HIV-2. These tests are available as blood tests or tests of oral fluid. HIV antibody tests can detect infections in most people 3-12 weeks after exposure.

Various options are available for getting tested:

• A blood or oral sample can be collected in a healthcare provider's office or a local clinic and sent to a laboratory for testing. In these same settings, a rapid test may available in which results are generated in about 20 minutes.
• A home collection kit approved by the U.S. Food and Drug Administration (FDA) is available for HIV antibody testing. This allows a person to take a sample at home and then mail it to a testing center. Results are available over the phone, along with appropriate counseling.
• The FDA has approved an HIV test for home use. The testing kit is the same as that used in many healthcare providers' offices and clinics in which an oral sample is collected for testing and results are available in about 20 minutes. Though the home test is convenient, it has limitations. It is less sensitive than a blood test so the home test may miss some cases of HIV that a blood test would detect and it is not as accurate when it is performed at home by a lay person compared to when it is performed by a trained healthcare professional. Care must be taken to avoid errors when performing the test. (For more, see the article on Home Testing, Avoiding Errors.)

Screening tests have limitations, so it is important to remember that:

• A negative screening test means only that there is no evidence of disease at the time of the test. If you have increased risk of HIV infection but negative screening results, it is very important to get screening tests on a regular basis.
• HIV tests will not detect the virus immediately after infection. Still, talk to your healthcare provider immediately if you think you’ve been infected. If exposure to the virus is recent, then antibody levels may be too low to detect. If an initial test is negative, it may be necessary to repeat testing at a later time with another antibody test or combination HIV antibody/antigen test. In the case of a negative result, the CDC recommends retesting three months after likely exposure.
• A positive screening test is not a diagnosis. A positive result must be followed by a second antibody test that differentiates between HIV-1 and HIV-2 to establish a diagnosis.

For more details on HIV screening, see the article on HIV Antibody and p24 Antigen.

Screening Recommendations

• The Centers for Disease Control and Prevention (CDC) recommends that everyone 13 to 64 years old have an HIV screening test at least once. The CDC recommends getting tested each year if you've engaged in an activity that can put you at increased risk of infection and spreading the disease. Additionally, men who have sexual contact with other men should be tested be tested every three to six months.
• The United States Preventive Services Task Force (USPSTF) recommends that all teens and adults ages 15 to 65 be screened for HIV infection. It also recommends that younger adolescents and older adults at increased risk undergo screening for HIV. As for how often, the Task Force says a reasonable approach is one-time testing for all people ages 15 to 65 and at least annual screenings for those at very high risk of HIV, such as men who have sex with men, injection drug users, and those who live or receive medical care in areas where the rate of HIV infection is high. Individuals at increased but not very high risk may be screened less frequently than every year. The USPSTF recommends every three to five years as a guideline. The Task Force points out that risk is "on a continuum" and health professionals should use their own discretion in deciding how frequently to test people for HIV.
• The American College of Physicians agrees with the CDC that everyone aged 13 to 64 be offered an HIV screening test in healthcare settings. It also recommends that healthcare practitioners should determine the frequency of repeat screening on an individual basis.
• The American Academy of Pediatrics (AAP) recommends targeted HIV screening for all sexually active youth. In addition, the academy advises routine testing starting at age 16 for all teens who live in areas where prevalence is high; that is, where more than 1 in 1,000 individuals are infected.
• For recommendations specific for pregnant women, see the article on Pregnancy.

Aside from these recommendations, certain individuals should get tested and learn their status. These include:

• People diagnosed with hepatitis, TB, or an STD
• People who received a blood transfusion prior to 1985 or had a sexual partner who received a transfusion and later tested positive for HIV
• A healthcare worker with direct exposure to blood on the job
• Any individual who thinks he or she may have been exposed

Talk to your healthcare provider
Don't be surprised if a healthcare practitioner, in any care setting, offers you an HIV screening test, in keeping with CDC recommendations. If your healthcare provider does not bring up sexual health topics, you can simply ask for a test or a risk assessment. You can also use confidential services to obtain testing or counseling.

---

Resources & Links

For confidential information, you can call the STDs and HIV/AIDS hotline of the CDC: 800-CDC-INFO (232-4636).
To find a testing site near you, visit National HIV and STD Testing Resources
KidsHealth.org: HIV and AIDS
MedlinePlus: Screening and diagnosis for HIV
Mayo Clinic: HIV/AIDS - Preparing for your appointment
AIDSinfo: HIV Testing

---

Sources Used in Current Review

Qaseem, A. et al. (2009 January 20). Screening for HIV in health care settings: A guidance statement from the American College of Physicians and HIV Medicine Association. Annals of Internal Medicine. Available online at http://annals.org/aim/article/744218/screening-hiv-health-care-settings-guidance-statement-from-american-college. Accessed 11/6/2016.

(2011 October 31). The pediatrician's role in preventing HIV infection. American Academy of Pediatrics. Available online at https://healthychildren.org/English/news/Pages/The-Pediatricians-Role-in-Preventing-HIV-Infection.aspx. Accessed 11/6/2016.

(2013 April). Human Immunodeficiency Virus (HIV) infection: Screening. U.S. Preventive Services Task Force. Available online at https://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/human-immunodeficiency-virus-hiv-infection-screening. Accessed 11/6/2016.

(2015 May 27). Press release: Starting antiretroviral treatment early improves outcomes for HIV-infected individuals. National Institutes of Health. Available online at https://www.nih.gov/news-events/news-releases/starting-antiretroviral-treatment-early-improves-outcomes-hiv-infected-individuals. Accessed 11/6/2016.

(Updated 2016 January 22). Working in healthcare and HIV. AVERT. Available online at http://www.avert.org/hiv-transmission-prevention/working-healthcare. Accessed 11/6/2016.

(2016 May 23). Recommendations for HIV prevention with adults and adolescents with HIV. Centers for Disease Control and Prevention. Available online at http://www.cdc.gov/hiv/guidelines/personswithhiv.html. Accessed 11/6/2016.

(2016 October 27). HIV and AIDS: Testing. Centers for Disease Control and Prevention. Available online at https://www.cdc.gov/hiv/basics/testing.html. Accessed 11/6/2016.

(2016 June 20). HIV testing. Centers for Disease Control and Prevention. Available online at https://www.cdc.gov/hiv/testing. Accessed 11/6/2016.

More Americans today die from hepatitis C than from HIV, according to a 2012 study by the Centers for Disease Control and Prevention (CDC). Although many people with hepatitis C (HCV) have no symptoms for decades, if left undiagnosed and unmanaged, hepatitis C infection can progress to chronic liver damage.

Over 2.7 million Americans are living with chronic HCV infection, which can cause long-term liver damage; without treatment, it is estimated that as many as half will develop cirrhosis and/or hepatocellular carcinoma, a type of liver cancer, both of which can be fatal. The CDC noted that the observed rise in deaths primarily affects those people born between 1945 and 1965, most of whom are unaware that they have even been infected by this slowly progressing disease.

Risk

Hepatitis C is spread by exposure to contaminated blood, for example, through sharing of needles during intravenous (IV) drug abuse. Though the risk is low, transmission can also occur through sexual activity and from an infected mother to her baby during childbirth. Prior to 1992, when HCV screening of donated blood became routine, it was also possible to become infected with HCV through blood transfusion or organ transplant. Health care workers who have been exposed to infected blood are also at risk.

Recommendations

• The CDC recommends one-time testing of all people born during the 1945-1965 time period, regardless of their risk factors for hepatitis C. Those who test positive should receive screening for alcohol use and intervention as needed, followed by referral to appropriate care for the hepatitis C infection and related conditions.
• Likewise, the United States Preventive Services Task Force (USPSTF) recommends screening for all adults at high risk of hepatitis C and for anyone born between 1945 and 1965, since prevalence is highest in this group.

Why get screening?

Many people who may have contracted the virus several years ago are unaware of their condition. A one-time test for older adults could detect infections contracted long ago, allowing for timely treatment and prevention of complications.

HCV-related disease and death is preventable if detected and treated. Before 2000, chronic HCV was curable in only 10% of cases. Now, treatments for HCV can cure over 90% of those detected before late complications occur.

---

Link
CDC: Hepatitis C FAQs for the Public

---

Sources Used in Current Review

U.S. Preventive Services Task Force. Hepatitis C: Screening. Release date: June 2013. Available online at http://www.uspreventiveservicestaskforce.org/Page/Document/UpdateSummaryFinal/hepatitis-c-screening. Accessed December 2015.

Ly K, et al. The Increasing Burden of Mortality From Viral Hepatitis in the United States Between 1999 and 2007. Ann Intern Med, February 21, 2012 vol. 156 no. 4 271-278. Available online http://www.annals.org/content/156/4/271.full. Accessed April 8, 2012.

Rein D, et al. The Cost-Effectiveness of Birth-Cohort Screening for Hepatitis C Antibody in U.S. Primary Care Settings. Ann Intern Med, February 21, 2012, vol. 156 no. 4, 263-269. Available online at http://www.annals.org/content/156/4/263-270. Accessed April 8, 2012.

Alter H.J, Liang T.J, Hepatitis C. The End of the Beginning and Possibly the Beginning of the End. Ann Intern Med, February 21, 2012, vol 156 no. 4, 317-318. Available online at http://www.annals.org/content/156/4/317. Accessed April 8, 2012.

Centers for Disease Control and Prevention. Recommendations for the Identification of Chronic Hepatitis C Virus Infection Among Persons Born During 1945–1965. Prepared by Smith, Bryce D. et al. MMWR. August 17, 2012. Available online at http://www.cdc.gov/mmwr/preview/mmwrhtml/rr6104a1.htm?s_cid=rr6104a1_w. Accessed August 2012.

MayoClinic.com. Hepatitis C risk factors. Available online at http://www.mayoclinic.com/health/hepatitis-c/DS00097/DSECTION=risk-factors. Accessed August 2012.

According to the Centers for Disease Control and Prevention (CDC), approximately 850,000 to 2.2 million people in this country have chronic infection with hepatitis B virus (HBV). Many of these people are unaware that they are infected.

HBV is one of five "hepatitis viruses" identified so far that are known to mainly infect the liver. It is spread through contact with blood or other body fluids from an infected person, such as during sex or by sharing needles, razors or toothbrushes, and can also be passed from an infected mother to her baby during or after birth.

HBV infection can be acute or chronic, with the course of infection varying from a mild form that lasts only a few weeks to a more serious form lasting years that can lead to complications such as cirrhosis or liver cancer. According to the CDC, approximately 1,800 people die every year in the U.S. from HBV-related liver disease.

The vast majority of those with chronic infections will have no symptoms. A test for hepatitis B surface antigen (HBsAg) may be used for screening asymptomatic people who fall into one of the high-risk categories for chronic HBV. Effective vaccines against HBV are available; however, those who have not been vaccinated or who are at high risk and were vaccinated before being screened for HBV infection may want to consider getting tested.

Recommendations
Since the prevalence of HBV infection is low in the general U.S. population and most of those infected do not develop complications, HBV screening is not recommended for those who are not at increased risk.

For people with increased risk of infection, several health organizations including the CDC, the American Association for the Study of Liver Diseases (AASLD) and the U.S. Preventive Services Task Force recommend screening for HBV. Examples of people at risk include:

• Healthcare and public safety workers with possible exposure to infected blood or other body fluid
• People born in areas of the world that have a greater than 2% prevalence of HBV (for example, much of Asia and Africa), regardless of whether they have been vaccinated
• People born in the U.S. but who were not vaccinated early in life and whose parents are from an area with greater than 8% prevalence of HBV
• Men who have sex with men
• Drug injection users
• People who have elevated liver enzymes (ALT and AST) with no known cause
• People with certain medical conditions that require that their immune system be suppressed, such as organ transplant recipients
• Dialysis patients
• People who are in close contact with someone infected with HBV or who have a sexual partner with HBV (i.e. tested positive for HBsAg)
• Those infected with HIV
• People who were vaccinated for HBV after they had already begun high-risk behavior (e.g., men who have sex with men and injection drug users)
   

In addition, the AASLD recommends HBV screening for:

• People with multiple sex partners
• Those who have a history of sexually transmitted diseases (STDs)
• Prison inmates
• People with hepatitis C infection
   

Why get tested?
People with chronic HBV can unknowingly spread the infection to others and remain at risk for serious complications of the infection.

---

Related Content
Tests: Hepatitis B Testing
Conditions: Hepatitis

---

Sources Used in Current Review (last reviewed 10/11/17)

LeFevre, M. (2014 July 1). Screening for Hepatitis B Virus Infection in Nonpregnant Adolescents and Adults: U.S. Preventive Services Task Force Recommendation Statement. Annals of Internal Medicine V 161 (1). Available online at https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/hepatitis-b-virus-infection-screening-2014. Accessed on 8/06/17.

(2016 May 23, Updated). Hepatitis B FAQs for the Public. Centers for Disease Control and Prevention. Available online at https://www.cdc.gov/hepatitis/hbv/bfaq.htm. Accessed on 8/06/17.

(2015 March). Guidelines for the Prevention, Care and Treatment of Persons with Chronic Hepatitis B Infection. World Health Organization. Available online at http://apps.who.int/iris/bitstream/10665/154590/1/9789241549059_eng.pdf Accessed on 8/06/17.

(2017 May 11 Updated). Viral Hepatitis. Centers for Disease Control and Prevention. Available online at https://www.cdc.gov/hepatitis/statistics/index.htm Accessed on 8/06/17.

(2016 August 4, Updated). Hepatitis B FAQs for Health Professionals. Centers for Disease Control and Prevention. Available online at https://www.cdc.gov/hepatitis/hbv/hbvfaq.htm. Accessed on 8/06/17.

Hillyard, D. and Slev, P. (2017 July Updated). Hepatitis B Virus – HBV. ARUP Consult. Available online at https://arupconsult.com/content/hepatitis-b-virus/?tab=tab_item-2. Accessed on 8/06/17.

Workowski, K. and Bolan, G. (2015). Sexually Transmitted Diseases Treatment Guidelines, 2015. MMWR June 5, 2015 / 64(RR3);1-137. Available online at https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6403a1.htm. Accessed on 8/06/17.

Chlamydia and gonorrhea are the most common bacterial sexually transmitted diseases (STDs) in the United States today, but many infected people have no symptoms. These infections usually affect the genitals but may also cause infections of other areas, such as the throat and rectum. Left untreated, these diseases can cause health complications. However, both diseases can be cured with antibiotics.

While rates of chlamydia and gonorrhea are highest in young people, any sexually active older adult can get a chlamydia or gonorrhea infection.

Recommendations for Women

The U.S. Centers for Disease Control and Prevention (CDC), the U.S. Preventive Services Task Force (USPSTF), the American Academy of Family of Physicians (AAFP), and the American College of Obstetricians and Gynecologists (ACOG) recommend chlamydia and gonorrhea screening for all sexually active older women who have risk factors, such as a new or multiple sex partners. The CDC specifically recommends annual screening.

Recommendations for Men

These organizations do not recommend routine screening for healthy, sexually active, heterosexual men. Health care providers may, however, use their judgment and consider risks, such as prevalence in the community. It is important to remember that an infected man can spread these diseases and even re-infect a partner if he does not complete treatment. For sexually active men who have sex with men, the CDC recommends chlamydia and gonorrhea screening at least annually.

Risk

Examples of risk factors include:

• Previous chlamydia or gonorrhea infections, even if you were successfully treated
• Having other STDs, especially HIV
• Having new or multiple sex partners
• Using condoms inconsistently
• Exchanging sex for money or drugs
• Using illegal drugs
• Living in a detention facility

Because reinfection rates are high, the CDC recommends that both women and men who are treated for chlamydia or gonorrhea infection be retested approximately 3 months after treatment or at their next health care visit, regardless of whether they believe that their sex partners were treated. It is important to continue annual screening for these diseases because reinfection is always possible.

---

Links

CDC: Get Tested, Find Free, Fast, and Confidential Testing Near You

---

Sources Used in Current Review (last reviewed 12/5/2017)

(2016 October 17, Updated). Chlamydia - CDC Fact Sheet (Detailed). Centers for Disease Control and Prevention. Available online at https://www.cdc.gov/std/chlamydia/stdfact-chlamydia-detailed.htm. Accessed on October 2017.

(2016 October 28, Updated). Gonorrhea – CDC Fact Sheet (Detailed Version). Centers for Disease Control and Prevention. Available online at https://www.cdc.gov/std/gonorrhea/stdfact-gonorrhea-detailed.htm. Accessed on October 2017.

(2016 December). Chlamydia, Gonorrhea, and Syphilis FAQ. American Congress of Obstetricians and Gynecologists. Available online at https://www.acog.org/Patients/FAQs/Chlamydia-Gonorrhea-and-Syphilis. Accessed on October 2017.

Fisher, M. and Schlaberg, R. (2017 July, Updated). Sexually Transmitted Infections. ARUP Consult. Available online at https://arupconsult.com/content/sexually-transmitted-infections/?tab=tab_item-1. Accessed on October 2017

(December 1, 2016) Centers for Disease Control and Prevention, STD Risk and Oral Sex - CDC Fact Sheet. Available online at https://www.cdc.gov/std/healthcomm/stdfact-stdriskandoralsex.htm. Accessed on October 2017.

(September 2014) US Preventive Services Task Force, Final Recommendation Statement Chlamydia and Gonorrhea: Screening. Available online at https://www.uspreventiveservicestaskforce.org/Page/Document/RecommendationStatementFinal/chlamydia-and-gonorrhea-screening. Accessed on October 2017.

Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis bacteria. TB primarily targets the lungs but may affect any area of the body. It can be spread through the air from person to person through droplets of respiratory secretions such as sputum or aerosols released by coughing, sneezing, laughing, or breathing.

Most people who become infected with M. tuberculosis manage to confine the mycobacteria to a few cells in their lungs, where they stay alive but in an inactive form. This latent TB infection does not make the person sick or infectious and, in most cases, it does not progress to active tuberculosis. However, some people - especially those with compromised immune systems - may progress directly from initial TB infection to active tuberculosis. People who have HIV are much more likely to become sick if they contract TB. A person who has latent TB and their immune system becomes weakened may then develop active TB. Another increasing concern is drug-resistant forms of TB that are resistant to the antibiotics typically prescribed to treat the disease.

TB is one of the world's deadliest diseases, although it is relatively uncommon in the U.S. Still, it is a large health issue among at-risk groups. Current guidelines call for targeted screening among such groups.

At Risk

• People who have close contact with a person who has known or suspected TB disease
• People with weakened immune systems such as resulting from HIV infection, malnutrition, advanced age, or substance abuse including alcohol and drugs
• Immigrants from countries with a high rate of TB disease (many countries in Latin America, Africa, Asia, Eastern Europe, and Russia)
• Medically underserved people, such as those from a low-income environment
• Residents of long-term care facilities (such as nursing homes, mental health facilities, prisons, AIDS care facilities, and homeless shelters)
• People who live in unclean or crowded environments and/or without a healthy diet
• Healthcare workers who work in any of the above situations or with patients who are at increased risk
• Laboratorians who work with specimens that may contain TB or with TB cultures

Recommendations

The U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Preventive Services Task Force (USPSTF) recommend use of TB tests to identify people who will likely benefit from treatment, including those at increased risk for M. tuberculosis infection or for progression to active TB if they are infected. There are two types of tests that might be performed:

• IGRA TB blood test (preferred): also known as Interferon gamma release assay, requires a blood sample to be drawn.
• Tuberculin skin test (TST) also called the Mantoux tuberculin skin test, the TST (or PPD for Purified Protein Derivative) is performed by injecting a small amount of fluid (called tuberculin) into the skin in the lower part of the arm. Following this test, you must return within 48 to 72 hours for a trained healthcare worker to measure the reaction and determine if it indicates exposure to M. tuberculosis.

 

---

Link
CDC: Tuberculosis (TB)

---

Sources Used in Current Review

Screening for Latent Tuberculosis Infection in Adults. US Preventive Services Task Force Recommendation Statement. JAMA. 2016;316(9):962-969. doi:10.1001/jama.2016.11046. Available online at http://jama.jamanetwork.com/article.aspx?articleid=2547762. Accessed October 2016.

U.S. Centers for Disease Control and Prevention. TB Testing & Diagnosis. Available online at http://www.cdc.gov/tb/topic/testing/. Accessed October 2016.